Patients with BRAF-mutant melanoma benefit from targeted and immunotherapy to a higher extent compared to patients with NRAS-mutant melanoma3, which underscores the necessity for novel targeted therapies and innovative drug combinations. The gene discussed is NRAS; the disease is melanoma.